Skip to main content
    T

    Twist Bioscience Corp (TWST)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $105.04
    -6.56 (-5.88%)

    Market Cap: $7.40B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Twist Bioscience Corp (TWST) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Twist Bioscience (TWST) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, Twist Bioscience reported EPS of -$0.32, above the -$0.43 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    64%(21/33)
    Avg Surprise
    -20.11%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.14
    Range-$0.31 - -$0.04
    3 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.10-45.3%
    60d ago-$0.16+12.8%
    30d ago-$0.16+12.8%
    7d ago-$0.16+12.8%
    Current-$0.14
    Revenue Consensus
    $126.42M
    Range$124.00M - $128.13M
    8 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.11
    Range-$0.30 - $0.00
    3 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.06-85.0%
    60d ago-$0.10-6.4%
    30d ago-$0.10-6.4%
    7d ago-$0.10-6.4%
    Current-$0.11
    Revenue Consensus
    $133.21M
    Range$130.10M - $136.32M
    8 analysts

    Next Report

    TWST has an expected report date of Feb 1, 2027.

    TWST Earnings Call

    The latest TWST earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 33 quarters below that had an estimate, TWST beat 21, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $126.64M, up 27.9% from $99.01M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.32-$0.43N/A+25.58%BeatN/A40 up, 1 downNov 12, 2026$126.64M
    Jun 30, 2026-$0.56-$0.50N/A-12.00%MissN/A20 up, 0 downAug 3, 2026$118.38M
    Mar 31, 2026-$0.60-$0.53-$0.53 - -$0.53-13.21%MissN/A10 up, 0 downMay 4, 2026$110.72M
    Dec 31, 2025-$0.50-$0.52-$0.52 - -$0.52+3.85%BeatN/A10 up, 0 downFeb 2, 2026$103.70M
    Sep 30, 2025-$0.45-$0.50-$0.50 - -$0.50+10.00%BeatN/A12 up, 1 downNov 14, 2025$99.01M
    Jun 30, 2025-$0.47-$0.57-$0.61 - -$0.52+17.54%BeatN/A31 up, 3 downAug 4, 2025$96.06M
    Mar 31, 2025-$0.66-$0.56-$0.59 - -$0.51-17.86%MissN/A52 up, 0 downMay 5, 2025$92.79M
    Dec 31, 2024-$0.53-$0.63-$0.65 - -$0.62+15.87%BeatN/A21 up, 0 downFeb 3, 2025$88.71M
    Sep 30, 2024-$0.59-$0.69-$0.73 - -$0.67+14.49%BeatN/A30 up, 1 downNov 18, 2024$84.71M
    Jun 30, 2024-$0.70-$0.77-$0.81 - -$0.73+9.09%BeatN/A100 up, 0 downAug 2, 2024$81.46M
    Mar 31, 2024-$0.79-$0.81-$0.86 - -$0.76+2.47%BeatN/A90 up, 1 downMay 2, 2024$75.30M
    Dec 31, 2023-$0.75-$0.77-$0.82 - -$0.72+2.60%BeatN/A91 up, 0 downFeb 2, 2024$71.50M
    Sep 30, 2023-$0.75-$0.86-$1.25 - -$0.80+12.79%BeatN/A90 up, 0 downNov 17, 2023$66.95M
    Jun 30, 2023-$1.02-$1.06-$1.23 - -$1.02+3.77%BeatN/A80 up, 0 downAug 4, 2023$63.74M
    Mar 31, 2023-$1.06-$1.10-$1.26 - -$1.02+3.64%BeatN/A90 up, 0 downMay 5, 2023$60.18M
    Dec 31, 2022-$0.81-$1.17-$1.26 - -$1.05+30.77%BeatN/A70 up, 0 downFeb 3, 2023$54.24M
    Sep 30, 2022-$1.01-$1.13-$1.40 - -$1.06+10.62%BeatN/A80 up, 0 downNov 18, 2022$57.31M
    Jun 30, 2022-$1.08-$1.31-$1.40 - -$1.18+17.56%BeatN/A72 up, 0 downAug 5, 2022$56.11M
    Mar 31, 2022-$1.02-$1.30-$1.33 - -$1.19+21.54%BeatN/A72 up, 0 downMay 5, 2022$48.13M
    Dec 31, 2021-$0.96-$1.06-$1.27 - -$0.95+9.43%BeatN/A8N/AFeb 4, 2022$42.02M
    Sep 30, 2021-$0.84-$0.79-$0.89 - -$0.70-6.33%MissN/A7N/ANov 22, 2021$37.95M
    Jun 30, 2021-$0.78-$0.75-$0.77 - -$0.73-4.00%MissN/A7N/AAug 6, 2021$35.02M
    Mar 31, 2021-$0.78-$0.78-$0.80 - -$0.720.00%In lineN/A5N/AMay 6, 2021$31.20M
    Dec 31, 2020-$0.72-$0.77-$0.78 - -$0.67+6.49%BeatN/A4N/AFeb 4, 2021$28.16M
    Sep 30, 2020-$0.54-$0.70-$0.77 - -$0.66+22.86%BeatN/A4N/ANov 23, 2020$32.43M
    Jun 30, 2020-$0.67-$0.88-$0.88 - -$0.55+23.86%BeatN/A3N/AAug 6, 2020$21.21M
    Mar 31, 2020-$0.85-$0.75-$0.83 - -$0.69-13.33%MissN/A4N/AMay 7, 2020$19.30M
    Dec 31, 2019-$1.00-$0.83-$0.95 - -$0.77-20.48%MissN/A3N/AFeb 6, 2020$17.16M
    Sep 30, 2019-$0.96-$0.83-$0.87 - -$0.78-15.66%MissN/A4N/ADec 11, 2019$15.74M
    Jun 30, 2019-$0.92-$0.82-$0.90 - -$0.76-12.20%MissN/A4N/AAug 1, 2019$13.60M
    Mar 31, 2019-$0.93-$0.97-$1.24 - -$0.82+4.12%BeatN/A3N/AApr 30, 2019$13.56M
    Dec 31, 2018-$1.18-$0.85-$0.94 - -$0.77-38.82%MissN/A3N/AFeb 7, 2019$11.49M
    Sep 30, 2018-$6.59-$0.75N/A-778.67%MissN/AN/AN/ANov 1, 2018$8.41M
    Jun 30, 2018-$0.66N/AN/AN/AN/AN/AN/AN/AAug 29, 2018$6.54M
    Last 34 quarters

    Annual EPS

    EPS for the fiscal year ended Sep 30, 2026 was -$1.98, after -$2.11 the year before. It was -$7.25 for the year ended Sep 30, 2018, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Sep 30, 2026-$1.98N/A
    Sep 30, 2025-$2.11N/A
    Sep 30, 2024-$2.83N/A
    Sep 30, 2023-$3.64N/A
    Sep 30, 2022-$4.07N/A
    Sep 30, 2021-$3.12N/A
    Sep 30, 2020-$3.06N/A
    Sep 30, 2019-$3.99N/A
    Sep 30, 2018-$7.25N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,900 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,85215
    2026Q2Jun 30, 20265,75015
    2026Q1Mar 31, 20266,37612
    2025Q4Dec 31, 20256,41214
    2025Q3Sep 30, 20255,74115
    2025Q2Jun 30, 20256,37515
    2025Q1Mar 31, 20256,40515
    2024Q4Dec 31, 20247,09516

    2026Q3 Earnings Call

    Opening remarks

    Angela Bitting SVP, Corporate Affairs Thank you, operator. Good morning, everyone. I'd like to thank you for joining us for Twist Bioscience's Conference Call to review our fiscal 2026 third quarter financial results and business progress. We issued our financial results press release before the market, and it is available at our website at www.twistbioscience.com. With me on the call today are Dr. Emily Leproust, CEO and Co-Founder of Twist; Adam Laponis, CFO of Twist; and Dr. Patrick Finn, President and COO of Twist. Today, we will discuss our business progress, financial and operational performance as well as growth opportunities. We'll then open the call for questions. We ask that you limit your questions to only one and then requeue as a courtesy to others on the call. This call is being recorded, and the audio portion will be archived in the Investors section of our website and will be available for 2 weeks. During today's presentation, we will make forward-looking statements within the meaning of the U.S. federal securities laws. Forward-looking statements generally relate to future events or future financial or operating performance. Our expectations and beliefs regarding these matters may not materialize, and actual results in financial periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks include those set forth in the press release we issued earlier today as well as those more fully described in our filings with the Securities and Exchange Commission. The forward-looking statements in this presentation are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law. We'll also discuss adjusted EBITDA, a financial measure that does not conform with generally accepted accounting principles. Information may be calculated differently than similar non-GAAP data presented by other companies. When reported, a reconciliation between GAAP and non-GAAP financial measures will be included in our earnings documents, which can be found on the Investors section of our website. With that, I will now turn the call over to our CEO and Co-Founder, Emily Leproust.

    Emily Leproust CEO & Co-Founder Thank you, Angela, and good morning, everyone. On Slide 3, you will see that this morning, we reported our 14th quarter of consistent growth with record revenue of $118.4 million, growth of 23% year-over-year. This growth reflects the diligence and execution we have employed over the last several years, building for opportunities we see ahead. Sometimes those opportunities are clearly visible many years in advance and others require us to be nimble and engage with our customers in real time to ensure we build and deliver what they need to be successful.

    Frequently Asked Questions About TWST

    When is Twist Bioscience's next earnings date?

    Twist Bioscience's next earnings report is expected for Feb 1, 2027.

    Did TWST beat earnings estimates last quarter?

    Yes. Twist Bioscience reported EPS of -$0.32 for the quarter ended Sep 30, 2026, above the -$0.43 estimate, a 25.58% surprise.

    What EPS do analysts expect from TWST next quarter?

    The consensus EPS estimate for Twist Bioscience for the quarter ending Dec 31, 2026 is -$0.14 from 3 analysts, with estimates from -$0.31 to -$0.04.

    How often does TWST beat earnings estimates?

    Twist Bioscience beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +3.72%.